SPRY vs VTRS
SPRY: ARS Pharmaceuticals has developed neffy, the first FDA-approved needle-free intranasal epinephrine spray for the emergency treatment of severe allergic reactions. VTRS: Viatris is a global healthcare company providing a broad range of high-quality, affordable medicines across both developed and emerging markets.
Side-by-side fundamentals
| Metric | SPRY | VTRS | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $4.18 | $18.45 | |
| Market cap | $416M | $21.2B | |
| Net margin FY2025, SEC XBRL | -203.3% | -24.6% | VTRS higher |
| Gross margin FY2025, SEC XBRL | n/a | +35.1% | |
| Operating margin FY2025, SEC XBRL | -212.9% | -18.6% | VTRS higher |
| ROE FY2025, SEC XBRL | -149.9% | n/a | |
| ROA FY2025, SEC XBRL | -52.3% | -9.5% | VTRS higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 7.73 | 0.94 | VTRS lower |
| Revenue growth (YoY) FY2025, SEC XBRL | -5.5% | -3.0% | VTRS higher |
| Revenue CAGR (3y) SEC XBRL | +300.1% | -4.2% | SPRY higher |
| Dividend yield as of 2026-09-02 | n/a | +2.8% | |
| Dividend streak (yrs) SEC XBRL | 0 | 5 | VTRS higher |
| Beta as of 2026-09-02 | 1.01 | 0.74 | |
| 1-year return as of 2026-10-21 close | -57.8% | +77.6% | VTRS higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.